Arecor Announces Exclusive Collaboration With Lilly on Formulation...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Arecor Announces Exclusive Collaboration With Lilly on Formulation Studies

Pharma Tech Outlook | Friday, June 04, 2021

Arecor leverages its proprietary formulation technology platform Arestat™ to create a differentiated, thermostable formulation of one of Lilly's proprietary self-administered products.

FREMONT, CA:  Arecor Limited, a biopharmaceutical company dedicated to bringing forth the new and improved therapies that will benefit and benefit humankind, declares the signing of a formulary partnership with Eli Lilly and Company.

As part of this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products intended for self-administration. By enhancing the thermostable formulation, patients will be able to use the product more conveniently without compromising the integrity of the product. In addition, Lilly will fund the research and development and acquire the rights to the new proprietary formulation and associated Intellectual Property through a technology licensing model to further develop and commercialize the product.

The new Arestat™ formulation technology is an innovative and proprietary formulation technology platform that enhances the properties of therapeutic proteins, peptides, and vaccines. Arestat™ applies the Arestat™ technology to both existing and new products in development and delivers higher quality reformulations of existing products.

Sarah Howell, Chief Executive Officer of Arecor, says, "We are delighted to be collaborating with Lilly again. We have always had a strong working relationship, and we believe that our  Arestat™ technology has the potential to deliver a new formulation that can improve the convenience of use of this critical self-administered product for Lilly’s patients. This collaboration with Lilly augments our partnership portfolio of major pharmaceutical companies and demonstrates how our formulation expertise can provide novel medical solutions for our partners.”

Arecor Limited is a biopharmaceutical company making transformative advances in patient care by bringing the latest therapies to market. They utilize proprietary Arestat™ technology to improve the efficacy of existing medicines and develop a comprehensive portfolio of therapies as part of their proprietary pipeline and partnership with prominent pharmaceutical and biotech companies. In addition, they design our treatments for people living with chronic disease to aid in patient care while also helping to increase medication adherence.

Weekly Brief

Read Also